Affinivax

Affinivax is now part of GSK. We’re no longer posting here, but you can continue to follow our story @GSKUS, or @GSK if you’re based outside of the US.

[Affinivax @Affinivax]

@GSK completes acquisition of Affinivax, Inc. https://t.co/2uL2bP3wki

[GSK US @GSKUS]

Yesterday we announced the completion of the acquisition of @Affinivax – including access to the exciting MAPS technology. Check this out to learn more 👇

[Affinivax @Affinivax]

#AheadTogether "We are very pleased to have found the ideal home within GSK..." @GSK x @Affinivax

[GSK US @GSKUS]

#News for #Investors and #Media. Today we announced the completion of the acquisition of @Affinivax. This news follows our recent acquisition of @sierraoncology as we continue to focus on developing a strong portfolio of innovative vaccines and specialty medicines.

[GSK @GSK]

#News for #Investors and #Media. Today @Affinivax joins GSK. We look forward to collaborating with this new extended team to deliver a promising new vaccine technology. More at: https://t.co/CMR2uu10h2

[Affinivax @Affinivax]

We're pleased to share the publication of data in the journal “Vaccines.” The article highlights foundational viral vaccine POC for our MAPS™ vaccine technology platform.
https://t.co/2YcyFEwzmT

[Affinivax @Affinivax]

Happy #PrideMonth! We celebrate Pride on this anniversary of the Stonewall Riots by reflecting on LGBTQIA+ history and striving towards greater visibility and equality. Support this community and the #NextGen Leaders here: https://t.co/evc5tSwWmS #PrideDay

[Affinivax @Affinivax]

We are delighted to share this publication in the journal Vaccine, detailing results from the Phase 2 clinical trial of our lead novel vaccine candidate targeting Streptococcus pneumoniae, which was developed using our proprietary MAPS™ platform. https://t.co/q6JdF7UAT9

[Affinivax @Affinivax]

In honor of #PrideMonth, we are proud to introduce Brandon Hagen, Sr. Manager, Corporate Communications, in our Employee Spotlights Series for June. See what “pride” means to him and why being your authentic self should always be the standard.

[Affinivax @Affinivax]

#ISPPD12 #MAPSnextgenvaccines https://t.co/PIFH2z8BnQ

[Affinivax @Affinivax]

At #ISPPD12, our poster presentation highlights the possibilities of engineering next generation pneumococcal vaccines. #MAPSnextgenvaccines https://t.co/PIFH2z8BnQ

[Affinivax @Affinivax]

Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine at the 12th International Symposium on Pneumococci and Pneumococcal Diseases https://t.co/PIFH2z8BnQ

[Affinivax @Affinivax]

Happy #Juneteenth2022! We take part in honoring this shared history which commemorates the anniversary of the news of freedom reaching enslaved Black Americans. We reflect on its significance and take stock of where we are still in the fight for equality. https://t.co/DiUPo3dpmz

[Affinivax @Affinivax]

It’s an exciting time at Affinivax and we are focused on the steadfast growth and opportunity within our Manufacturing department. Check out these open roles! https://t.co/bjsY07iBAe #WereHiring #SimplePowerfulVaccines

[Affinivax @Affinivax]

We’re excited to present next week at #ISPPD12 – E-poster Spotlight Talk, Session 04: Vaccine and Vaccine Trials on Monday, June 20th between 4:55-5:55PM EDT.

[Affinivax @Affinivax]

As we look ahead to an exciting future, we also look back on what the Affinivax team achieved. We built our MAPS™ platform from Boston Children’s Hospital & a pipeline of novel vaccines with our lead vaccine candidate in late-stage clinical studies. https://t.co/qOCSwT9R4f

[Affinivax @Affinivax]

With the proposed acquisition news today, we envision that @GSK's significant capabilities will enable continued advances with MAPS™ to improve upon existing vaccines and address unmet need for diseases without current immunization strategies. https://t.co/qOCSwT9R4f

[GSK US @GSKUS]

#News for #Investors and #Media. Today, we’ve announced the proposed acquisition of @Affinivax. If approved, this will further strengthen our vaccine pipeline and provides access to a new, potentially disruptive technology.
https://t.co/Rv5aqsV2Pu

[Affinivax @Affinivax]

Today, we announced the proposed acquisition of Affinivax by @GSK for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. https://t.co/qOCSwT9R4f

[Affinivax @Affinivax]

@GSK to acquire clinical-stage biopharmaceutical company, Affinivax, Inc. https://t.co/qOCSwT9R4f